

Current and Future Clinical Studies

- 2001 to date Drotrecogin Alfa (Activated) for Use in Acute Renal Failure Patients Managed With Continuous Renal Replacement Therapy.
Sponsor: Eli Lilly and Company.
S. Noor Rahman, M.D.
- 2001 to date A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated with Hemodialysis.
Sponsor: Amgen, Inc.
S. Noor Rahman, M.D.
- 2000 to date Genetic susceptibility to Diabetic Nephropathy.
Sponsor: NIH
S. Noor Rahman, M.D.
- 2000 to date Pilot Study on the Impact of Anemia Correction on Left Ventricular Hypertrophy in Subjects with Chronic Insufficiency, without Symptomatic heart Disease, Treated with Novel Erythropoiesis Stimulating Protein.
Sponsor: Amgen, Inc.
S. Noor Rahman, M.D.
- 2000 to date A Randomized pilot Study to Assess the Impact of Anemia Correction with Novel Erythropoiesis Stimulating Protein on Health-related Quality of Life and Activities of Daily Living in Subjects with Chronic Renal Insufficiency (CRI).
Sponsor: Amgen, Inc.
S. Noor Rahman, M.D.
- 2000 to date A study Evaluating the Initiation and Titration of Fixed Doses of Novel Erythropoiesis Stimulating Protein (NESP) Therapy In Subjects with Chronic Renal Insufficiency (CRI).
Sponsor: Amgen, Inc.
S. Noor Rahman, M.D.
- 2000 to date A randomized, double-blind, placebo-controlled, multicenter, long-term trial of preventing hypertension using Candesartan Cilexetil 16 mg in patients with high normal blood Pressure.
Sponsor: Astra Zeneca, L. P.
S. Noor Rahman, M.D.

1998 to date A prospective, multinational, multicenter, double blind, randomized, active-controlled trial in patients with essential hypertension to compare the effect of Valsartan 80 mg and 160 mg, with or without the addition of hydrochlorothiazide, once daily to that of hydrochlorothiazide on cardiovascular morbidity and mortality.
Sponsor: Novartis Pharmaceuticals Inc.
S. Noor Rahman, M.D.

Upcoming Studies.

2001 to date EARTH: Evaluation of Atherosclerotic Outcomes with Rosuvastatin Therapy (EARTH) Study.
Sponsor: Astra Zeneca, L. P.
S. Noor Rahman, M.D.

2001 to date CHOIR: Correction of Hemoglobin and Outcomes In Renal Insufficiency.
Sponsor: Ortho Biotech Products, L. P.
S. Noor Rahman, M.D.

2002 ARANESP: A study of Derbepoetin alfa administered once every four weeks in chronic renal insufficiency (CRI) subjects with anemia.
Sponsor: Amgen, Inc.
S. Noor Rahman, M.D.